Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bafetinib

Next Previous
Drug Profile

Bafetinib

Alternative Names: BCR-ABL/Lyn Kinase Inhibitors; CNS-9; INNO-406; NS-187

Latest Information Update: 29 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer LadRx Corporation
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-Abl tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bone resorption; Brain cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
  • 07 May 2014 Bafetinib is available for licensing as of 07 May 2014. http://www.cytrx.com
  • 18 Mar 2013 CytRx completes a phase I trial in Brain cancer in USA (NCT01234740)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top